Market Overview:
The global autoimmune disease therapeutics market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of autoimmune diseases, rising awareness about these diseases, and technological advancements in the field of autoimmune disease therapeutics. The global autoimmune disease therapeutics market is segmented on the basis of type into immunosuppressants, anti-inflammatory drugs, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), biologics, and others. The immunosuppressants segment is expected to dominate the global autoimmune disease therapeutics market during the forecast period owing to their high efficacy in treating various types of autoimmune diseases. The anti-inflammatory drugs segment is projected to grow at a higher CAGR than other segments during the forecast period due to their wide usage for treating various types of inflammatory conditions associated with autoimmunity.
Product Definition:
Autoimmune disease therapeutics are drugs that are used to treat autoimmune diseases. These drugs can help to suppress the immune system and help to reduce inflammation. The importance of autoimmune disease therapeutics is that they can help to improve the quality of life for people who suffer from these diseases.
Immunosuppressants:
The global immunosuppressants, it's usage and growth factor in autoimmune disease therapeutics market size was valued at USD 4.8 billion in 2015 and is expected to grow at a CAGR of XX% over the forecast period. The increasing prevalence of autoimmune diseases such as rheumatoid arthritis, psoriasis, lupus & systemic sclerosis along with rising geriatric population base is primarily driving the growth of this market globally.
Anti-Inflammatory Drugs:
The global anti-inflammatory drugs and it's usage in autoimmune disease therapeutics market size was valued at USD 14.1 billion in 2016 and is expected to grow at a CAGR of XX% over the forecast period. The rising prevalence of chronic diseases, such as rheumatoid arthritis, psoriasis, Crohn’s disease, etc., has led to an increase in drug consumption globally.
Application Insights:
The others segment held the largest share of over 30.0% in 2017. The other applications include rheumatoid arthritis, osteoarthritis, gout, lupus and multiple sclerosis. Osteoarthritis is expected to be the fastest-growing application owing to increasing prevalence of the disease coupled with a growing number of product launches for this condition in recent years. For instance, in June 2016 Pfizer launched Celebrex (celecoxib) tablets for treatment of osteoarthritis pain worldwide; whereas Biogen Inc introduced Taltz (ixekizumab) injection for treating osteoporosis pain worldwide in September 2016.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing prevalence of autoimmune diseases are some factors responsible for its growth. In addition, growing awareness about available treatment options is expected to drive the regional market during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising healthcare expenditure by governments and private organizations as well as increasing prevalence of autoimmune disorders in this region. Moreover, improving healthcare infrastructure and growing patient awareness levels are also contributing toward regional market development during the same period.
Growth Factors:
- Increasing incidence of autoimmune diseases
- Growing awareness about autoimmune diseases and their treatments
- Rising demand for better and more effective therapies for autoimmune diseases
- Technological advances in the field of autoimmune disease therapeutics
- increasing investment in research and development for new therapies for autoimmune diseases
Scope Of The Report
Report Attributes
Report Details
Report Title
Autoimmune Disease Therapeutics Market Research Report
By Type
Immunosuppressants, Anti-Inflammatory Drugs, Corticosteroids, Nonsteroidal Anti-inflammatory Drugs, Biologics, Others
By Application
Hospitals, Clinics, Independent Pharmacies, Others
By Companies
Pfizer, Novartis, Johnson & Johnson Services, Merck, Sanofi, Abott, Bristol-Myers Squibb, Amgen, Bayer, F. Hoffmann-La Roche, Eli Lilly and Company
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
152
Number of Tables & Figures
107
Customization Available
Yes, the report can be customized as per your need.
Global Autoimmune Disease Therapeutics Market Report Segments:
The global Autoimmune Disease Therapeutics market is segmented on the basis of:
Types
Immunosuppressants, Anti-Inflammatory Drugs, Corticosteroids, Nonsteroidal Anti-inflammatory Drugs, Biologics, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Independent Pharmacies, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis
- Johnson & Johnson Services
- Merck
- Sanofi
- Abott
- Bristol-Myers Squibb
- Amgen
- Bayer
- F. Hoffmann-La Roche
- Eli Lilly and Company
Highlights of The Autoimmune Disease Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Immunosuppressants
- Anti-Inflammatory Drugs
- Corticosteroids
- Nonsteroidal Anti-inflammatory Drugs
- Biologics
- Others
- By Application:
- Hospitals
- Clinics
- Independent Pharmacies
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Autoimmune Disease Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Autoimmune disease therapeutics is a field of research and development focused on the discovery, development, and commercialization of novel therapies for autoimmune diseases. These therapies may be designed to target specific components or mechanisms of the immune system that are responsible for causing or exacerbating these diseases.
Some of the key players operating in the autoimmune disease therapeutics market are Pfizer, Novartis, Johnson & Johnson Services, Merck, Sanofi, Abott, Bristol-Myers Squibb, Amgen, Bayer, F. Hoffmann-La Roche, Eli Lilly and Company.
The autoimmune disease therapeutics market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Autoimmune Disease Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Autoimmune Disease Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Autoimmune Disease Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Autoimmune Disease Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Autoimmune Disease Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Autoimmune Disease Therapeutics Market Size and Y-o-Y Growth
4.5.2 Autoimmune Disease Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Autoimmune Disease Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Autoimmune Disease Therapeutics Market Size Forecast by Type
5.2.1 Immunosuppressants
5.2.2 Anti-Inflammatory Drugs
5.2.3 Corticosteroids
5.2.4 Nonsteroidal Anti-inflammatory Drugs
5.2.5 Biologics
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Autoimmune Disease Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Autoimmune Disease Therapeutics Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Independent Pharmacies
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Autoimmune Disease Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Autoimmune Disease Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Autoimmune Disease Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Autoimmune Disease Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Autoimmune Disease Therapeutics Market Size Forecast by Type
9.6.1 Immunosuppressants
9.6.2 Anti-Inflammatory Drugs
9.6.3 Corticosteroids
9.6.4 Nonsteroidal Anti-inflammatory Drugs
9.6.5 Biologics
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Autoimmune Disease Therapeutics Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Independent Pharmacies
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Autoimmune Disease Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Autoimmune Disease Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Autoimmune Disease Therapeutics Market Size Forecast by Type
10.6.1 Immunosuppressants
10.6.2 Anti-Inflammatory Drugs
10.6.3 Corticosteroids
10.6.4 Nonsteroidal Anti-inflammatory Drugs
10.6.5 Biologics
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Autoimmune Disease Therapeutics Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Independent Pharmacies
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Autoimmune Disease Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Autoimmune Disease Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Autoimmune Disease Therapeutics Market Size Forecast by Type
11.6.1 Immunosuppressants
11.6.2 Anti-Inflammatory Drugs
11.6.3 Corticosteroids
11.6.4 Nonsteroidal Anti-inflammatory Drugs
11.6.5 Biologics
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Autoimmune Disease Therapeutics Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Independent Pharmacies
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Autoimmune Disease Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Autoimmune Disease Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Autoimmune Disease Therapeutics Market Size Forecast by Type
12.6.1 Immunosuppressants
12.6.2 Anti-Inflammatory Drugs
12.6.3 Corticosteroids
12.6.4 Nonsteroidal Anti-inflammatory Drugs
12.6.5 Biologics
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Autoimmune Disease Therapeutics Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Independent Pharmacies
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Autoimmune Disease Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Autoimmune Disease Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Autoimmune Disease Therapeutics Market Size Forecast by Type
13.6.1 Immunosuppressants
13.6.2 Anti-Inflammatory Drugs
13.6.3 Corticosteroids
13.6.4 Nonsteroidal Anti-inflammatory Drugs
13.6.5 Biologics
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Autoimmune Disease Therapeutics Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Independent Pharmacies
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Autoimmune Disease Therapeutics Market: Competitive Dashboard
14.2 Global Autoimmune Disease Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Novartis
14.3.3 Johnson & Johnson Services
14.3.4 Merck
14.3.5 Sanofi
14.3.6 Abott
14.3.7 Bristol-Myers Squibb
14.3.8 Amgen
14.3.9 Bayer
14.3.10 F. Hoffmann-La Roche
14.3.11 Eli Lilly and Company
